Moby15m agoneutral
Novo Nordisk Swallows the Bitter PillThe Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline stumble.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
490last 24h
2474last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
Zacks1h agoneutral
Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
InvestorsHub1h agoneutral
Eli Lilly shares climb after stronger revenue outlook driven by obesity drugsEli Lilly (NYSE:LLY) rose more than 5% in pre-market trading on Wednesday after the pharmaceutical company increased its full-year revenue guidance, supported by continued strong demand for its blockbuster diabetes and weight-loss treatments. The revised outlook outweighed an earnings-per-share miss for the second quarter, as investors focused on accelerating sales growth and improved profitability expectations.
24/7 Wall St.1h agoneutral
GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its FutureEli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may not be what defines the company a decade from now. A billion-dollar bet on artificial intelligence could change everything.
GuruFocus.com1h agoneutral
Eli Lilly's Weight-Loss Engine Is Still AcceleratingZepbound and Mounjaro helped drive a major earnings beat and a higher sales outlook.
Stocktwits1h agoneutral
Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’Lilly’s second-quarter revenue jumped 48% and comfortably beat Wall Street estimates, driven primarily by strong demand for its blockbuster weight loss drugs Mounjaro and Zepbound.
Reuters Videos2h agoneutralVIDEO
Novo Nordisk looks to future proof as investors worry over pipeline<body><p>STORY: :: Novo Nordisk</p><p>'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.''</p><p>:: How is Novo Nordisk future proofing as investors worry about pipeline?</p><p>:: August 5, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent </p><p>''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. ''</p><p>'''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.''</p><p>:: What is CEO Mike Doutsdar's response?</p><p>:: Novo Nordisk</p><p>''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development. And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''</p></body>
Investor's Business Daily2h agoneutral
Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares PopEli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity.
PA Media: Money2h agoneutral
Mounjaro sales double this year as obesity drug boom prevails, says makerThe manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.
Investing.com3h agoneutral
Eli Lilly shares pop as weight-loss drug demand fuels guidance hikeInvesting.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs.
The Wall Street Journal4h agoneutral
Eli Lilly Posts Higher Revenue on Continued GLP-1 DemandEli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs.
Barrons.com4h agoneutral
AMD, Nvidia, Intel, Booking, and More Stocks That Explain Today’s MarketFEATURE Stock futures were rising on Wednesday, putting both the and the on track to notch record highs. SpaceX slumped 11% in premarket trading after the rockets, telecom, and AI company beat analysts’ second-quarter earnings target but reported higher capital expenditure than Wall Street was expecting.
The Wall Street Journal8h agoneutral
Jobs Report, Berkshire Earnings: What to Watch the Rest of the WeekToday Federal Reserve speakers: Fed governor Lisa Cook Economic data: the Energy Information Administration’s weekly petroleum status report, U.S. services PMI, global services PMI, ADP employment survey Earnings (a.
Barrons.com21h agoneutral
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.
GuruFocus.com21h agoneutral
Lilly Opens Pre-Approval Access to Its Next Obesity DrugLilly plans to file for FDA approval in the first quarter of next year
Insider Monkey1d agoneutral
Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market?Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Zacks1d agoneutral
Pfizer (PFE) Q2 Earnings and Revenues Top EstimatesPfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Barrons.com1d agoneutral
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are OpenEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Investopedia1d agoneutral
Here’s How Much Traders See Eli Lilly Stock Moving After EarningsEli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.
Pharma Voice1d agoneutral
Three potential takeover targets in psychedelicsLilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
The Wall Street Journal1d agoneutral
SpaceX Earnings, Jobs Numbers: What to Watch This WeekToday Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
Barrons.com1d agoneutral
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or NotEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Proactive1d agoneutral
Amplia Therapeutics partners with Lilly on lung cancer combination trialAmplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in patients with advanced non-small cell lung cancer (NSCLC). The...
MarketBeat1d agoneutral
Inspire Medical Systems Q2 Earnings Call HighlightsInspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting
